ArticleChembiochem : a European journal of chemical biology2025
Advancing the Exploration of the Ubiquitin-like Protein FUBI with Synthetic Chemical Tools.
Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Covalent Traps to Fluorescent Beacons: The Expanding Arsenal of Chemical Probes for Studying Ubiquitin and Ubiquitin-Like Proteins.Angewandte Chemie (International ed. in English) · 2026Review
- Selective Lysine Ubiquitination Using Activated Phenol Esters.Chembiochem : a European journal of chemical biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The Ubiquitin-like protein FUBI is encoded in humans by the FAU gene, whose down-regulation in prostate, ovarian and breast cancer is significantly associated with poor prognosis. Despite its implications in disease progression, the regulatory mechanisms orchestrated by FUBI remain elusive. To address this knowledge gap, a linear synthetic platform is developed to generate FUBI chemical tools, enabling the site-specific incorporation of unnatural building blocks and the introduction of fluorophores, tags, and reactive warheads. Using this platform, activity-based probes are created for FUBI conjugation and deconjugation enzymes, validating them in cell lysate-based assays and proteomics. Additionally, a triazole-linked Di-FUBI is synthesized to investigate FUBI chain modulators. Among the proteomics hits, IMPDH1 and the deubiquitinase UCHL3 are identified as novel Di-FUBI specific interactors. Further characterization revealed that Di-FUBI inhibits UCHL3 cleavage activity in a concentration-dependent manner, suggesting a novel regulatory interplay between UCHL3 and FUBI. Collectively, these tools demonstrate the versatility of the synthetic FUBI platform, advancing the characterization of FUBI-related enzymes in the ongoing efforts to decipher the complex code of ubiquitin-like signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.